As the largest Indian industry group – the Indian Pharmaceutical Alliance – has forecast close to trebling the market turnover from USD50 billion now to USD130 billion over the next six years, that task may get daunting and without pushing for some big changes, achieving it may get tougher.
To move from cost-based to value-based, Indian pharma needs radical reforms and a bold attitude
- Blog
